MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla

Ja, auf die iNeST Daten (Phase 2) zu BNT122 (Melanoma) warten wir seit schon seit dem letzten Jahr. Hiernach wurde immer wieder gefragt bei den letzten Q&A im Rahmen der Präsentation der Quartalszahlen. Datenauslese hat sich verzögert aufgrund der Verzögerungen bei der Probandenrekrutierung in der Pandemie. Siehe hierzu: Chris Shibutani: „Yes, two questions if I can, one on the pipeline and the other more financially related. On the pipeline, BNT122 first-line metastatic melanoma seemed a bit conspicuous in terms of the absence of mention in the press release and in prepared comments. I do see it in the pipeline table. Have your expectations for this trial changed? I believe we should still be expecting updates in the balance of this year.“ Ryan Richardson -- Chief Strategy Officer „Yeah, thanks, Chris. Let me start on the -- on the 122 and Ozlem can also chime in here. So, we've reiterated our -- our guidance for an update later this year. We still intend to provide that. I think on -- on a previous call, we had also mentioned that the -- the full -- the PFS analysis would be triggered on an event basis. And the fact is we still haven't met that event trigger -- reached that event trigger, which does -- which does mean that we're not in a position right now to be specific about the full -- the data that we're likely to bring out later this year. So, we do intend to provide an update before year-end, but I think it's likely that there won't be a full data update. So, more to come on that.“ Ozlem Tureci -- Co-Founder and Chief Medical Officer „Yeah, I can just echo what -- what Ryan -- Ryan said. Gathering these events is not entirely under our control. And therefore, we, at this point, cannot -- cannot forecast when we will be able to report the data interim analysis data point.“

eigentlich sollte doch auch bald mal ein Update zu BNT122 kommen? Melanom: https://classic.clinicaltrials.gov/ct2/show/NCT03815058?term=RO7198457&draw=2&rank=2 (Estimated Study Completion Date : April 1, 2024) https://classic.clinicaltrials.gov/ct2/show/NCT04486378?term=BioNTech&cond=Colorectal+Cancer&draw=2&rank=1 (Estimated Primary Completion Date : September 2023)

@Benny80 egal wieviel Menschen sich impfen lassen, bestellt werden muss trotzdem auf Vorrat. Sonst hat man nicht genug wenn mehr gebraucht wird. Ich weß gerade nicht, was an Grippeimpfstoff jährlich vernichtet wird, in anderen Jahren reicht er kaum aus